From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases.

Immune checkpoints negatively regulate immune response, thereby playing an important role in maintaining immune homeostasis. Substantial studies have confirmed that blockade or deficiency of immune checkpoint pathways contributes to the deterioration of autoimmune diseases. In this context, focusing on immune checkpoints might provide alternative strategies for the treatment of autoimmunity. Lymphocyte activation gene 3 (LAG3), as a member of immune checkpoint, is critical in regulating immune responses as manifested in multiple preclinical studies and clinical trials. Recent success of dual-blockade of LAG3 and programmed death-1 in melanoma also supports the notion that LAG3 is a crucial regulator in immune tolerance. We wrote this review article by searching the PubMed, Web of Science and Google Scholar databases. In this review, we summarize the molecular structure and the action mechanisms of LAG3. Additionally, we highlight its roles in diverse autoimmune diseases and discuss how the manipulation of the LAG3 pathway can serve as a promising therapeutic strategy as well as its specific mechanism with the aim of filling the gaps from bench to bedside. © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Citation

Xueyin Zhou, Yiming Gu, Huihong Wang, Wei Zhou, Lei Zou, Shuting Li, Chunyan Hua, Sheng Gao. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2023 Jun;72(6):1215-1235

Mesh Tags

Substances

PMID: 37314518

search → result